JPRN-UMIN000021864已完成未知
Bortezomib, Low Dose Cyclophosphamide and G-CSF in Promoting Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant - Bortezomib, Low Dose Cyclophosphamide and G-CSF in Promoting Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant
Ochanomizu Hematology Study Group0 个研究点目标入组 8 人开始时间: 2016年5月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Patient has hypersensitivity to bortezomib, cyclophosphamide, and G-CSF. (2)Patient has Grade =>2 peripheral neuropathy (3)Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, cardiac amyloidosis (4)Known interstitial Pneumonitis (5)Uncontrolled intercurrent infection (6)Known HBs antigen positive, HCV antibody positive (7)Known HTLV-I antibody positive, HIV antibody positive (8)Female patients who are pregnant and/or breastfeeding. (9)Active gastrointestinal bleeding (10)Serious psychiatric illness (11)A co-morbid condition which, in the view of the investigators, renders the patient at high risk for this study
研究者
相似试验
已完成
2 期
Bortezomib, cyclophosphamide plusd dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myelomaJPRN-UMIN000009765Kanagawa Cancer Center30
尚未招募
3 期
A comparison of Bortezomib, Pomalidomide with low-dose Dexamethasone and Bortezomib, Lenalidomide with low-dose dexamethasone for newly-diagnosed multiple myeloma patients- A randomized phase III study.CTRI/2019/07/020397Dr Lalit Kumar
招募中
2 期
Intermediate-cyclophosphamide and bortezomib for peripheral blood stem cell mobilization in multiple myelomamultiple myelomaJPRN-UMIN000011503Department of Hematology, Ishikawa Prefectural Central Hospital20
进行中（未招募）
1 期
A study for adults with Waldenstrom's macroglobulinaemia to investigate whether a new combination of 3 drugs (Bortezomib, Cyclophosphamide and Rituxumab) is safe and gives better response to treatment.Waldenstrom's macroglobulinaemia (WM)MedDRA version: 14.1Level: LLTClassification code 10054695Term: Waldenstrom's macroglobulinemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-005156-34-GBniversity College London56
进行中（未招募）
不适用
Bortezomib in combination with continuous low-dose oral cyclophosphamide and dexamethason followed by maintenance in primary refractory or relapsed bortezomib naïve multiple myeloma patientsEUCTR2008-004822-17-NLniversity Medical Center